Hillen et al., 2013 - Google Patents
FRI0258 Decreased tslp expression in labial salivary glands of patients with primary sjögren's syndrome is associated with increased t and b cell inflammation and …Hillen et al., 2013
- Document ID
- 8251121753756184196
- Author
- Hillen M
- Kruize A
- Bikker A
- Wenting-van Wijk M
- Radstake T
- Lafeber F
- Hack C
- van Roon J
- Publication year
- Publication venue
- Annals of the Rheumatic Diseases
External Links
Snippet
Background Thymic Stromal Lymphopoietin (TSLP) is a potent immunomodulatory cytokine involved in Th2-mediated immune responses and homeostatic T-cell expansion. Reduced TSLP expression by intestinal epithelial cells was recently shown to lead to reduced Th2 …
- 210000003079 Salivary Glands 0 title abstract description 12
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Iijima et al. | Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus | |
| US10980874B2 (en) | Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors | |
| Petro et al. | Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease | |
| Gottstein et al. | Susceptibility versus resistance in alveolar echinococcosis (larval infection with Echinococcus multilocularis) | |
| Furuichi et al. | Depletion of CD25+ CD4+ T cells (Tregs) enhances the HBV-specific CD8+ T cell response primed by DNA immunization | |
| Keymeulen et al. | Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients | |
| Vermeulen et al. | Suppression of NK cells and regulatory T lymphocytes in cats naturally infected with feline infectious peritonitis virus | |
| Maxwell et al. | T cell clonal conditioning: a phase occurring early after antigen presentation but before clonal expansion is impacted by Toll-like receptor stimulation | |
| Srivastava et al. | A herpes simplex virus type 1 human asymptomatic CD8+ T-cell epitopes-based vaccine protects against ocular herpes in a “humanized” HLA transgenic rabbit model | |
| Khan et al. | Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of local PD-1+ TIM-3+ CD8+ exhausted T cells | |
| Mutsvunguma et al. | Identification of multiple potent neutralizing and non-neutralizing antibodies against Epstein-Barr virus gp350 protein with potential for clinical application and as reagents for mapping immunodominant epitopes | |
| US10918712B2 (en) | Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors | |
| US10532064B2 (en) | Biophosphonate compounds and gamma delta T cell-mediated therapy for treating epstein-barr virus-associated disorders | |
| JP2020097569A (en) | Treatment and functional cure of hiv infection with anti-cd4 monoclonal antibodies that mediate competitive hiv entry inhibition | |
| Freeman et al. | Gammaherpesvirus latency induces antibody-associated thrombocytopenia in mice | |
| Hopfer et al. | Glomerulopathy induced by immunization with a peptide derived from the goodpasture antigen α3IV-NC1 | |
| Moss et al. | EBV-specific immune response: early research and personal reminiscences | |
| Croia et al. | FRI0259 Ectopic lymphoid structures support epstein-barr virus persistence and autoreactive plasma cell infection in sjogren’s syndrome salivary glands | |
| Hillen et al. | FRI0258 Decreased tslp expression in labial salivary glands of patients with primary sjögren’s syndrome is associated with increased t and b cell inflammation and tissue destruction | |
| US20220088185A1 (en) | Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors | |
| Najimi et al. | Unravelling humoral immunity in SARS-CoV-2: Insights from infection and vaccination | |
| CA3124523A1 (en) | Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors | |
| US20240041994A1 (en) | Cmv vaccine and method of making and using the same | |
| Wu et al. | Vaccine targeting TNF epitope 1–14 do not suppress host defense against Mycobacterium bovis Bacillus Calmette-Guérin infection | |
| Hoxha et al. | FRI0260 Defining the pathogenetic autoantibodies in congenital heart block |